Obtain more insight in the preferred macronutrient composition of an oral nutritional supplement.
ID
Source
Brief title
Condition
- Other condition
- Muscle disorders
Synonym
Health condition
Onderzoek vindt plaats in gezonde ouderen en ouderen met sarcopenie
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Mixed muscle protein fractional synthetic rate (FSR) [%/h]
Secondary outcome
Plasma leucine (Leumax [umol/L]; LeuiAUC [umol/(L*min)])
Plasma essential amino acids (EAAmax [umol/L]; EAAiAUC [umol/(L*min)])
Background summary
Ageing is accompanied by a progressive decline of skeletal muscle mass and
function which is named sarcopenia. Loss of muscle function is associated with
a decline in mobility and independecy and an increased risk for falling. A
possible cause of sarcopenia is a decreased muscle protein synthesis.
Specifically for elderly Danone Reseach developed an oral nutritional
supplement (ONS) aiming to increase muscle protein synthesis. In this study we
will investigate the macronutrient composition of the ONS on skeletal muscle
protein synthesis in elderly.
This reserach will give more insight in the preferred macronutrient composition
of the ONS.
Study objective
Obtain more insight in the preferred macronutrient composition of an oral
nutritional supplement.
Study design
Randomized, controlled, double-blind, parallel-group, single-centre study in
healthy elderly
Single-arm study in sarcopenic elderly
Intervention
One single-bolus of one of the three study products
Study burden and risks
For both visits subjects arrive in a fasted state
During the screening visit an oral glucose tolerance test will be performed.
The subject has to consume a glucose drink (300 ml) and 1x 10 ml and 4 x 5 ml
blood (total volume of 30 mL) is collected. The only risk of blood sampling is
a small hematoma.
Functional test are performed to calculate the SPPB score which is used to
discriminate between healthy and sarcopenic elderly. Body composition is
measured with Dxa. Dxa is a simple, non-invasive procedure which exposes the
subjects to a very low dose of radiation (i.e. <1 µSv). No risks associated
with this procedure are expected.
All subjects are instructed to refrain from alcohol consumption (24 h) and
intense physical activities (72 h) prior to the study visit and keep their
normal dietary habits (except from fasting from 22:00 h the evening preceding
the study visit). All subjects consume a standardized meal the evening prior to
the study visit.
During the study visit we will record medication use during last 3 days prior
to study visit. To be able to meaure muscle protein synthesis we will collect
24 x 8 ml blood (total volume of 192 ml) en 4 muscle biopsies. Both blood
sampling and muscle biopsy collection can cause a small hematoma. Bleedings
and/or infections rarely occur. Muscle biopsy itself can be painfull, but is
generally well tolerated. Later on the day of the muscle biopsy and/or in the 2
days after, the muscle can feel a bit sore. This feels like general
delayed-onset muscle soreness after exercise and will be completely healed
after 2 days.
The subjects will consume 1 single bolus of one the three study products (150
mL). Before and 5 hour after product intake gastrointestinal tolerance will be
assessed with an gastrointestinal tolerance questionaire.
Uppsalalaan 12
Utrecht 3584 CT
NL
Uppsalalaan 12
Utrecht 3584 CT
NL
Listed location countries
Age
Inclusion criteria
- Age 65 y or older
- Male
- Healthy (n = 45) or sarcopenia (n = 15)
- BMI from 20 through 30 kg/m2
- Written informed consent
Exclusion criteria
- Indications related to inadequate glycemic control
- All co-morbidities interacting with mobility and/or muscle metabolism of the lower limbs
- Any (history of) gastrointestinal disease that interferes with GI function
- Diabetes Mellitus type I or II
- Adherence to a weight loss diet
- Use of protein containing or amino acid containing nutritional supplements within one week of study entry
- Participation in any regular exercise program focusing on improving skeletal muscle mass
- Known allergy to milk and milk products
- Known galactosaemia
- Blood diseases, use of anticoagulants or allergy for lidocaine, because of muscle biopsy collection
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL36765.068.11 |